新药领域中高剂量疗法的时机选择。

Timing of the high-dose therapy in the area of new drugs.

作者信息

Schmitt Stefan, Bertsch Uta, Hose Dirk, Goldschmidt Hartmut

机构信息

Department of Medicine V, University of Heidelberg, Heidelberg, Germany.

出版信息

Srp Arh Celok Lek. 2011 Dec;139 Suppl 2:90-4. doi: 10.2298/sarh11s2090s.

DOI:10.2298/sarh11s2090s

PMID:22352189

Abstract

The treatment approach in patients with multiple myeloma (MM) has been essentially changed with introduction of novel agents such as thalidomide, bortezomib and lenalidomide. In patients eligible for autologous stem cell transplant, combinations of novel agents with chemotherapy have been recognized as induction regimens. New induction regimens have significantly increased the rate of complete remission before and after autologous stem cell transplant with positive impact on the length of progression-free survival followed by the possibility for further improvement with the application of consolidation or use of thalidomide and lenalidomide as maintenance therapy. These results offer new perspectives in the treatment of MM with a reasonable hope of cure.

摘要

随着沙利度胺、硼替佐米和来那度胺等新型药物的引入，多发性骨髓瘤（MM）患者的治疗方法发生了根本性改变。对于适合自体干细胞移植的患者，新型药物与化疗的联合已被认可为诱导方案。新的诱导方案显著提高了自体干细胞移植前后的完全缓解率，对无进展生存期的延长产生了积极影响，随后通过巩固治疗或使用沙利度胺和来那度胺作为维持治疗有可能进一步改善。这些结果为MM的治疗提供了新的视角，带来了治愈的合理希望。